Nuanced Health develops a drug discovery and development platform by systematically humanizing mouse microbiomes to account for environmental drivers of disease. This approach utilizes next-generation preclinical models that recreate the heterogeneity of human populations, addressing the limitations of traditional singular animal models. The platform generates high-resolution multi-omic datasets and actionable insights to enhance the translatability and efficacy prediction of novel therapeutics.
Funding
$0 raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AOFPCFounders
Product
Problem
Traditional preclinical drug development relies on animal models that do not accurately represent the microbial diversity and environmental influences present in human populations. These models often fail to predict therapeutic efficacy and safety in clinical trials due to the significant differences between animal and human biology. This leads to costly failures and delays in bringing new drugs to market.
Solution
Nuanced Health offers a drug-discovery platform that humanizes the mouse microbiome to create preclinical models that better reflect the heterogeneity of human populations. By transplanting diverse human microbiomes into mice, the platform recreates the environmental imprint on human biology, enabling the study of diverse disease progression and drug response phenotypes. The platform generates high-resolution multi-omic datasets at scale, which are then analyzed using bioinformatics and machine learning to provide actionable insights. This approach enhances the predictability of therapeutic efficacy and safety, addressing the limitations of traditional animal models in drug development.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in preclinical drug discovery and development.
Features
- Scalable humanization of the mouse microbiome with diverse human samples
- Generation of high-resolution multi-omic datasets, including genomic, proteomic, and metabolomic data
- Advanced bioinformatics and machine learning analysis for identifying key biomarkers and predicting drug response
- Preclinical models that recreate diverse disease progression and drug response phenotypes observed in the clinic
- Ability to interrogate the environmental imprint on human biology